Anzeige
Mehr »
Donnerstag, 23.07.2026 - Börsentäglich über 12.000 News
Aktie im Fokus: Gelingt jetzt der Turnaround?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D54P | ISIN: US21833P3010 | Ticker-Symbol: 3371
Stuttgart
22.07.26 | 21:56
7,720 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CORBUS PHARMACEUTICALS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CORBUS PHARMACEUTICALS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,5457,88007:26
7,5757,88007:26

Aktuelle News zur CORBUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.07.Corbus Pharmaceuticals beruft Leonardo Nicacio zum Chief Medical Officer1
06.07.Corbus Pharmaceuticals names Leonardo Nicacio as CMO1
CORBUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.07.Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as Chief Medical Officer1
06.07.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report1
06.07.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer232NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies...
► Artikel lesen
17.06.Corbus Pharmaceuticals Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
29.05.Corbus Pharmaceuticals Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
26.05.Corbus slips after updated trial data for cancer candidate10
26.05.Mizuho raises Corbus Pharmaceuticals stock price target to $44 on ASCO data confidence9
26.05.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers368Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9%...
► Artikel lesen
22.05.Corbus Pharmaceuticals: Mizuho hebt Kursziel vor ASCO-Datenpräsentation an3
21.05.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report2
12.05.Jefferies cuts Corbus Pharmaceuticals stock price target on HNSCC data4
12.05.Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report1
12.05.Corbus Pharmaceuticals GAAP EPS of -$1.23 beats by $0.021
12.05.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update443Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of...
► Artikel lesen
12.05.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report-
23.04.Clean Energy Fuels appoints Clay Corbus as CEO3
22.04.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-7014
17.04.Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value4
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1